The mechanism of action of mRNA vaccines goes far beyond harnessing host cellular machinery to produce antigenic proteins to spur immunity, write Nicolas Hulscher, M.P.H., Peter A. McCullough, M.D., M ...
The cold season is in full swing, throats are scratchy and noses are running. We feel ill and hope it is not the flu. The ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) ("BioVaxys") and Adiverna LLC ("Adiverna") announce today that they have entered into a Research Agreement ...
ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...
A team from University of Toronto Engineering is the first to synthesize long noncoding RNA (lncRNA) outside the cell—a new approach to drug discovery that has already yielded some promising ...
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow ...
Explore the breakthrough of lab-made lncRNA by University of Toronto Engineering for new drug discovery potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results